[{"orgOrder":0,"company":"Intrance Medical System","sponsor":"Erik Selin","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"Carbidopa","moa":"||DOPA decarboxylase","graph1":"Neurology","graph2":"IND Enabling","graph3":"Intrance Medical System","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Intrance Medical System \/ Erik Selin","highestDevelopmentStatusID":"5","companyTruncated":"Intrance Medical System \/ Erik Selin"},{"orgOrder":0,"company":"Lobsor Pharmaceuticals","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Lobsor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lobsor Pharmaceuticals \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Lobsor Pharmaceuticals \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Etilevodopa","moa":"||Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"STADA Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"STADA Arzneimittel \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Entacapone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinsonâ€...

                          Product Name : Lecigon

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 04, 2022

                          Lead Product(s) : Carbidopa,Entacapone,Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Erik Selin

                          Deal Size : $17.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2021

                          Lead Product(s) : Etilevodopa,Carbidopa,Entacapone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          October 02, 2020

                          Lead Product(s) : Etilevodopa,Carbidopa,Entacapone

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : STADA Arzneimittel

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Entacapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 23, 2014

                          Lead Product(s) : Entacapone

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank